drugset / Trial / NCT00078611

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

NCT00078611

Phase 3 Completed 462 enrolled Biogen Elan Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.

Timeline

Start
2004-03
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody Intravenous

Indications